Here is a reading list: Dosage for other indications.

New Post Public Reply Private Reply Replies (2) Message Board
MD VIROLOGIST
1,091
Here is a reading list:

Dosage for other indications. For some indications only a single dose is required, but for others the dose may need to be repeated 2-3 times.
2. L Caly et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020 April 3 (epub).
3. National Institutes of Health (NIH). Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available at: https://covid19treatmentguidelines.nih.gov/. Accessed January 18, 2021.
4. FDA letter to stakeholders: do not use ivermectin intended for animals as treatment for COVID-19 in humans. Available at: https://www.fda.gov/animal-veterinary/product...-19-humans. Accessed August 29, 2020.
5. JC Rajter et al. Use of ivermectin is associated with lower mortality in hospitalized patients with COVID-19 (ICON study). Chest 2020 October 12 (epub; in press).
6. G Momekov and D Momekova. Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens.
MedRxiv 2020 May 22. Available at: https://www.medrxiv.org/content/10.1101/2020....20061804v2. Accessed October 26, 2020.
7. R Mahmud et al. Clinical trial of ivermectin plus doxycycline for the treatment of confirmed COVID-19 infection. ClinicalTrials.gov. Available at:
https://clinicaltrials.gov/ct2/show/results/NCT04523831. Accessed October 26, 2020.
8. HA Hashim et al. Controlled randomized clinical trial on using ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq. MedRxiv 2020 October 27 (epub). Available at:
https://www.medrxiv.org/content/10.1101/2020....20219345v1. Accessed November 4, 2020.
9. S Ahmed et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis 2021; 103:214.
10. AZK Chachar et al. Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients. Int J of Sci 2020; 9:31.
11. ATMM Chowdhury et al. A randomized trial of ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID-19 patients. Research Square 2020 (preprint).
12. P Soto-Becerra et al. Real-world effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using
observational data from a nationwide healthcare system in Peru. medRxiv 2020 October 14 (epub).
13. A Elgazzar et al. Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic. Research Square 2020 December 28 (epub).
14. MS Niaee et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: a randomized multi-center clinical trial. Research Square 2020 November 24 (epub).
15. E Lopez-Medina et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. JAMA 2021; 325:1426
6. A Bhimraj et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. Available at: https://www.idsociety.org/practiceguideline/c...anagement/. Accessed March 29, 2021.
17. YM Roman et al. Ivermectin for the treatment of COVID-19: a systematic review and meta-analysis of randomized controlled trials. medRxiv 2021 May 25 (epub). Available at:
https://www.medrxiv.org/content/10.1101/2021....21257595v1. Accessed May 27, 2021.
18. A Hill et al. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. Open Forum Infect Dis 2021 July 6 (accepted manuscript).
19. J Vallejos et al. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial. BMC Infect Dis 2021; 21:635.
20. News Release. AMA, APhA, ASHP statement on ending use of ivermectin to treat COVID-19. Available at: https://www.ama-assn.org/press-center/press-r...t-covid-19. Accessed September 7, 2021.
21. CDC Health Advisory. Rapid increase in ivermectin prescriptions and reports of severe illness associated with use of products containing ivermectin to prevent or treat COVID-19. Available
at: https://emergency.cdc.gov/han/2021/pdf/CDC_HAN_449.pdf. Accessed September 7, 2021.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stellus Capital Delivers Solid Q3 Amid Turbulent Times

Updated Category News Views 67

Unpacking Stellus Capital's Latest Quarter Boy, Stellus Capital sure knows how to keep us on our toes. In a landscape where many are still reeling from the latest market tremors, they post some solid Q3 numbers for September 30, 2026. Not without its hiccups, but hey, who isn’t stumbling a bit right now? Financial Snapshot: Stability Amidst Uncertainty Stellus reported...

Continue Reading
Safeguard Global Scores with Atlético Partnership

Updated Category News Views 24

Kicking Off a New Chapter in Workforce Management Well, when a global workforce giant teams up with a football powerhouse like Atlético de Madrid, it sure does mark a significant play on the field of employment strategies. Safeguard Global has just inked a multi-year partnership with Atlético, signing on as their Official Workforce Partner in Spain. It's not every day...

Continue Reading
Americans Grapple with Stagnant Personal Finances: Survey

Updated Category News Views 18

Americans' Financial Struggles Uncovered The economic landscape seems like a grizzled veteran who's seen its fair share of battles, but lately, it's been hitting families square in the wallet. According to Achieve's latest survey, a stark 71% of Americans are staring at finances that are either stuck in neutral or sliding backwards. Less than half say they’re in a good...

Continue Reading
Daycare Drama: Lawsuit Over Child in Traffic Incident

Updated Category News Views 107

When Chaos Meets Daycare Negligence Fort Worth is no stranger to wild stories, but when a daycare loses a child, you've got a whole different beast. Picture this: a 2-year-old girl, barely tall enough to peek over her own shadow, found by herself on a high-traffic road. That's not just someone's bad day—it's a lawsuit waiting to explode. And boy, has it ever. Parents...

Continue Reading
Texas Author's Memoir Journeys Through Trauma and Growth

Updated Category News Views 101

Finding Clarity Amid Chaos When life throws the unexpected, some folks crumble, but others, like Joyce L. Skala, sift through the rubble for clarity. Her debut memoir, "There's No Such Thing as Bad," weaves through personal chaos—embracing trauma and loss like a late-night poker game where the house always wins. Born from the charred memories of her family's home...

Continue Reading
Quest Diagnostics at Jefferies Conference: What’s Next?

Updated Category News Views 65

Quest Diagnostics Set for the Spotlight in London You're sipping your morning coffee when you hear that Quest Diagnostics (NYSE: DGX) is gearing up for a fireside chat in the UK's capital. Now, this isn't a random chit-chat we're talking about. Sam Samad, the man handling the books as their CFO, will be chatting it up at the Jefferies Global Healthcare Conference on...

Continue Reading
Marketing Maven Hosts Claude Workshop for Small Biz

Updated Category News Views 15

Diving into Claude for Business Out in Ventura County, California, there's a buzz about a fresh, no-cost workshop on deck. Marketing Maven's Lindsey Carnett and Design Main Street's Will Hsiao are teaming up to crack open the potential of Claude for small businesses. And let me tell you, this ain't your typical Monday seminar—it's setting up to provide the golden...

Continue Reading
Spotlight on Shenzhen: Malcolm Clarke Unveils a New Lens

Updated Category News Views 86

A Fresh Gaze on Shenzhen's Dynamic Pulse When's the last time a glossy documentary slapped you awake? That's the vibe Oscar-winning filmmaker Malcolm Clarke is gunning for with his latest, Shenzhen: People Who Build the Future. Forget the cookie-cutter skyline shots, this one's peeling back layers and going beyond the surface gloss. From Pioneers to Futurists: Shenzhen's...

Continue Reading
Mesh Security Bolsters Team with Five Cybersecurity Experts

Updated Category News Views 238

New Blood in Cybersecurity: Mesh's Strategic Moves Ever felt like the cybersecurity world is in a constant game of catch-up? You're not wrong. In today's digital battleground, companies don't just need more tools—they need collective wisdom to bind it all together. And it seems like Mesh Security just caught onto that notion, stacking their deck with five new...

Continue Reading
FuelCell Energy Class Action Deadline Looms Amid Loss Reports

Updated Category News Views 42

November Deadline for FCEL Class Action Participation You've probably seen the stars align in all the wrong ways if you've got stakes in FuelCell Energy, Inc. (NASDAQ: FCEL) right now. A class action lawsuit is breathing down everyone's neck, with a cut-off date of November 10, 2026, to hop aboard. If you bought into FuelCell between June 24 and September 1 of this year,...

Continue Reading

Top 5 Most Recently Viewed Articles

DouYu International Holdings Posts Noteworthy Q2 Financial Gains

Updated Category News Views 187

DouYu International's Financial Performance in Q2 2025 DouYu International Holdings Limited (NASDAQ: DOYU), a leader in the game-centric live streaming domain, has shared its financial outcomes for the second quarter of 2025, marking a significant transformation in its profitability amidst a competitive landscape. Key Financial Highlights For the second quarter of 2025,...

Continue Reading
Philips Receives Jefferies Upgrade Highlighting Market Challenges

Updated Category News Views 262

Philips Stock Upgraded by Jefferies Amid Market Struggles Recently, Koninklijke Philips NV (PHIA:NA) (NYSE:AS:PHG) caught the attention of Jefferies, a prominent financial services firm, as it upgraded its stock rating from Underperform to Hold. This decision was not made lightly; it reflects a careful analysis of Philips' recent financial performance in a challenging...

Continue Reading
RGP's First Quarter FY2025 Results Show Revenue Challenges

Updated Category News Views 135

Financial Performance Overview Resources Connection, Inc. (RGP), a professional service firm, unveiled its financial results for the first quarter of fiscal 2025. The firm experienced a notable decline in revenue, totaling $136.9 million, signifying a 19.5% decrease compared to the prior year. First Quarter Highlights Key Financial Metrics Revenue decreased to $136.9...

Continue Reading
PTS's Innovative Partnerships Set New Standards in Bitcoin Mining

Updated Category News Views 227

PTS Signs Strategic Agreements with Leading Bitcoin Mining Firms Pivotal Trend Service Co., Ltd. (PTS), a digital asset company recognized for its innovative approaches, has forged important long-term agreements with some of the most respected Bitcoin mining companies in the industry. This move is a significant step towards delivering compliant and stable Bitcoin-based...

Continue Reading
The Incredible Growth of Marathon Petroleum Investment Over a Decade

Updated Category News Views 180

Understanding Marathon Petroleum's Growth Over Time Marathon Petroleum (NYSE:MPC) has shown remarkable performance in the last decade, surpassing market expectations with annualized returns of 13.61%. As of now, this leading oil refining company boasts a market capitalization of approximately $59.51 billion. This impressive growth highlights the potential of investments...

Continue Reading